Medical Education Library

An Approach to the Management of Type 2 Diabetes Mellitus in Patients Receiving Add-On Therapy With Colesevelam HCl


 

A Journal Scan supplement to Clinical Endocrinology News. This supplement was sponsored by Daiichi Sankyo, Inc.

Topics

• Introduction
• Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): A Randomized, Double-Blind, Placebo-Controlled Pilot Study Evaluating the Effect of Colesevelam Hydrochloride on Glycemic Control in Subjects with Type 2 Diabetes
• Efficacy and Safety of Colesevelam in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Receiving Insulin-Based Therapy
• Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy
• Colesevelam Hydrochloride Therapy in Patients With Type 2 Diabetes Mellitus Treated With Metformin: Glucose and Lipid Effects

Faculty/Faculty Disclosures

Endocrinologist:
Harold E. Bays, MD, FACP, FACE
Medical Director/President
Louisville Metabolic and
Atherosclerosis Research Center
Louisville, Kentucky

Dr Bays has research grants, consultant fees, and speaker fees with Abbott Laboratories, Aegerion Pharmaceuticals, Akros Pharma Inc, Amarin, Amgen Inc., Amylin Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., Arete Therapeutics Inc., AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim Corporation, Cargill, Inc., Daiichi Sankyo, Inc., Eli Lilly and Company, Essentialis, Inc., GlaxoSmithKline plc, Hoffmann-La Roche Inc., Home Access Health Corporation, InteKrin Therapeutics Inc., Isis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc.,Merck/Schering-Plough Pharmaceuticals, Metabolex, Inc., Neuromed Pharmaceuticals Ltd., NicOx, Novo Nordisk A/S, Orexigen Therapeutics, Inc., Pfizer Inc., Purdue Pharma L.P., sanofi-aventis US LLC, Sciele Pharma, Inc., Surface Logix, Inc., Takeda Pharmaceutical Company Limited, and VIVUS Inc.


Cardiologist:
Peter H. Jones, MD
Associate Professor of Medicine
Baylor College of Medicine
Houston, Texas

Dr Jones has consulting agreements with Abbott Laboratories, AstraZeneca, Daiichi Sankyo, Inc., and Merck/Schering-Plough Pharmaceuticals.


Copyright © 2010 Elsevier Inc.

To view the supplement, click the image above.

Recommended Reading

ACP, Consumer Reports Collaborate on Treatment Guidelines for Consumers
MDedge Endocrinology
Health Officials to Docs: Help Save ACA
MDedge Endocrinology
Statins' Effect on Pneumonia Mortality Murky in Meta-Analysis
MDedge Endocrinology
Insulin Degludec Matches Insulin Glargine Efficacy
MDedge Endocrinology
Problematic Physician Behavior Can Be Cured
MDedge Endocrinology
Alternative Statin Regimens Reduce Muscle Pain
MDedge Endocrinology
CASE STUDY: Management Decisions in a Comorbid Patient With Type 2 Diabetes Having Primary Hyperlipidemia
MDedge Endocrinology
A1c Management and Modest Weight Loss in Type 2 Diabetes
MDedge Endocrinology
BEST PRACTICES IN:Preventing Hypoglycemia by Continuous Glucose Monitoring
MDedge Endocrinology
BEST PRACTICES IN: Continuous Glucose Monitoring and Multiple Daily Injections
MDedge Endocrinology